Sarepta Therapeutics Inc（SRPT）財務資料SRPTSarepta Therapeutics Inc

Sarepta Therapeutics, Inc. (SRPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is PMO Products, accounting for 57.5% of total sales, equivalent to $230.56M. Other significant revenue streams include ELEVIDYS and collaboration and other. Understanding this composition is critical for investors evaluating how SRPT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Sarepta Therapeutics, Inc. maintains a gross margin of 62.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.03%, while the net margin is -1.22%. These profitability ratios, combined with a Return on Equity (ROE) of -9.48%, provide a clear picture of how effectively SRPT converts its operational activities into shareholder value.

In the context of the broader market, SRPT competes directly with industry leaders such as OCUL and HRMY. With a market capitalization of $2.45B, it holds a leading position in the sector. When comparing efficiency, SRPT's gross margin of 62.59% stands against OCUL's 85.08% and HRMY's 75.81%. Such benchmarking helps identify whether Sarepta Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Sarepta's Q2 2026 revenue was $401 million, a decline from $611 million a year earlier, but it achieved GAAP operating profitability, indicating effective cost management. The gross margin for Q2 was 62.59%, which is still relatively strong despite the decline in revenue.